menu search

Checkpoint therapeutics reports full-year 2022 financial results and recent corporate highlights

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous ...

March 31, 2023, 12:00 am

Patient death prompts macrogenics to close mid-stage head & cancer study

MacroGenics Inc (NASDAQ: MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or m...

July 11, 2022, 6:42 am

Bristol myers' (bmy) opdivo combos get fda nod for escc

Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophagea...

May 30, 2022, 4:33 pm

Checkpoint therapeutics: potential upside based on marketing application submissions

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with ...

April 18, 2022, 2:15 pm

Agilent (a) boosts pd-l1 ihc 28-8 pharmdx use in european union

Agilent Technologies (A) boosts its presence in the companion diagnostics market by expanding the use of PD-L1 IHC 28-8 pharmDx assay for esophageal <...

April 7, 2022, 12:48 pm

Fda clears lyell immunopharma' lyl132 trial for solid tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...

January 24, 2022, 12:39 pm

Fda clears lyell immunopharma' lyl132 trial for solid tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...

January 24, 2022, 12:39 pm

Fda clears lyell immunopharma' lyl132 trial for solid tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...

January 24, 2022, 12:39 pm


Search within

Pages Search Results: